Marea Therapeutics

Marea Therapeutics is a clinical-stage biotechnology company leveraging the latest advances in human genetics to develop first-in-class next-generation drugs for cardiometabolic diseases. The company’s lead program, MAR001, is currently in Phase 2 clinical development for reducing residual cholesterol in adults at high risk of metabolic dysfunction and cardiovascular disease. Marea is led by a dynamic team of scientists and company builders with deep expertise and experience in cardiometabolic diseases, human genetics, and adipocyte biology.